News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BaroFold, Inc. Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron™


6/16/2008 1:15:49 PM

BOULDER, Colo.--(BUSINESS WIRE)--BaroFold Inc. announced today that it has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron™ (IFNß-1b).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES